Skip to main content
. Author manuscript; available in PMC: 2014 May 1.
Published in final edited form as: Mycoses. 2012 Nov 22;56(3):10.1111/myc.12024. doi: 10.1111/myc.12024

Table 1.

Characteristics of 24 noncatheterized patients with hematologic malignancies and candiduria

Characteristic n (%)
Race
 White 11 (46)
 Hispanic 7 (29)
 Othera 6 (25)
Hematologic malignancy
 AML/MDS 12 (50)
 ALL 4 (17)
 NHL 2 (8)
 CLL 2 (8)
 Otherb 4 (17)
GvHDc 2 (8)
Hypoalbuminemia (<3 mg/dl) c 8 (33)
Prior immunosuppressive therapyd,e 7 (29)
Prior corticosteroid use (>600 mg)d 4 (17)
Prior ICU stayd 4 (17)
History of urinary tract abnormalityf 2 (8)
Presence of central venous catheterc 15 (63)
Concomitant infectiond,g 19 (79)
 Respiratory tract 12 (50)
 Urinary tracth 9 (37)
 Otheri 4 (17)
Prior antifungal used,j 12 (50)
 Azoles
  Fluconazole 4 (17)
  Voriconazole 4 (17)
  Posaconazole 1 (4)
  Itraconazole 1 (4)
 Echinocandins 3 (13)
  Caspofungin 2 (8)
  Anidulafungin 1 (4)
Urinalysis findings (n = 21)
 Proteinuria 16 (76)
 Hematuria 3 (14)
 Pyuria 9 (43)
 Casts 6 (29)
 Glycosuria 5 (24)
 Nitrites 4 (19)
Candida speciesk
C. glabrata 9 (38)
C. albicans 7 (29)
C. tropicalis 6 (25)
C. krusei 1 (4)
C. kefyr 1 (4)
C. parapsilosis 1 (4)

NOTE. AML, acute myeloblastic leukemia; MDS, myelodysplastic syndrome; ALL, acute lymphoblastic leukemia; NHL, non-Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; GvHD, graft-versus-host-disease.

a

Black (n = 5) Asian (n = 1).

b

Multiple myeloma, chronic myelogenous leukemia, aplastic leukemia, and myelofibrosis (one each).

c

At the time of candiduria diagnosis.

d

In the month prior to candiduria diagnosis.

e

Immunosuppressive regimens such as tacrolimus and tumor necrosis factor inhibitor.

f

The first patient reported a history of ureteric stent placement (4 months before candiduria diagnosis), nephrolithiasis, and recurrent UTIs, and the second underwent ureteric stent placement (5 days before candiduria diagnosis) for ureter obstruction secondary to lymph node enlargement.

g

Some patients had more than one site of infection.

h

Coagulase-negative Staphylococcus species (n = 5), Enterococcus species (n = 2), Escherichia coli (n = 1), Pseudomonas aeruginosa (n = 1), and Staphylococcus aureus (n = 1) (one patient had 2 different pathogens).

i

Varicella-zoster virus infection (n = 1), acute cholecystitis (n = 1), and cellulitis (n = 2).

j

One patient received two different antifungals.

k

One patient had two different Candida spp.